| [1] |
Wang Y, Zhao L, Gao L, et al. Health policy and public health implications of obesity in China [J]. Lancet Diabetes Endocrinol, 2021, 9(7): 446-461.
|
| [2] |
Bray GA, Kim KK, Wilding JPH, et al. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation [J]. Obes Rev, 2017, 18(7): 715-723.
|
| [3] |
Hurt RT, Edakkanambeth Varayil J, Mundi MS, et al. Designation of obesity as a disease: lessons learned from alcohol and tobacco [J]. Curr Gastroenterol Rep, 2014, 16(11): 415.
|
| [4] |
Avgerinos KI, Spyrou N, Mantzoros CS, et al. Obesity and cancer risk: Emerging biological mechanisms and perspectives [J]. Metabolism, 2019, 92: 121-135.
|
| [5] |
Mendez-Sanchez N, Chavez-Tapia NC, Uribe M. Gallbladder disease and obesity.[J]. Gac Med Mex, 2004, 140(Suppl 2): S59-66.
|
| [6] |
Cariou B, Chetiveaux M, Zaïr Y, et al. Fasting plasma chenodeoxycholic acid and cholic acid concentrations are inversely correlated with insulin sensitivity in adults [J]. Nutr Metab (Lond), 2011, 8(1): 48.
|
| [7] |
Glicksman C, Pournaras DJ, Wright M, et al. Postprandial plasma bile acid responses in normal weight and obese subjects [J]. Ann Clin Biochem, 2010, 47(Pt 5): 482-484.
|
| [8] |
Haeusler RA, Astiarraga B, Camastra S, et al. Human insulin resistance is associated with increased plasma levels of 12alpha-hydroxylated bile acids [J]. Diabetes, 2013, 62(12): 4184-4191.
|
| [9] |
Watanabe M, Houten SM, Wang L, et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c [J]. J Clin Invest, 2004, 113(10): 1408-1418.
|
| [10] |
Sayin SI, Wahlström A, Felin J, et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist [J]. Cell Metab, 2013, 17(2): 225-235.
|
| [11] |
European Association for the Study of the Liver (EASL). Electronic address: easloffice@easloffice.eu. EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones [J]. J Hepatol, 2016, 65(1): 146-181.
|
| [12] |
Wang DQ, Cohen DE, Carey MC. Biliary lipids and cholesterol gallstone disease [J]. J Lipid Res, 2009, 50 Suppl(Suppl): S406-411.
|
| [13] |
Aune D, Norat T, Vatten LJ. Body mass index, abdominal fatness and the risk of gallbladder disease [J]. Eur J Epidemiol, 2015, 30(9): 1009-1019.
|
| [14] |
Méndez-Sánchez N, Chávez-Tapia NC, Zamora-Valdés D, et al. Hepatobiliary diseases and insulin resistance [J]. Curr Med Chem, 2007, 14(18): 1988-1999.
|
| [15] |
Leitzmann MF, Giovannucci EL, Rimm EB, et al. The relation of physical activity to risk for symptomatic gallstone disease in men [J]. Ann Intern Med, 1998, 128(6): 417-425.
|
| [16] |
Portincasa P, Di Ciaula A, Palmieri V, et al. Effects of cholestyramine on gallbladder and gastric emptying in obese and lean subjects [J]. Eur J Clin Invest, 1995, 25(10): 746-753.
|
| [17] |
Hou L, Shu XO, Gao YT, et al. Anthropometric measurements, physical activity, and the risk of symptomatic gallstone disease in Chinese women [J]. Ann Epidemiol, 2009, 19(5): 344-350.
|
| [18] |
Parra-Landazury NM, Cordova-Gallardo J, Méndez-Sánchez N. Obesity and Gallstones [J]. Visc Med, 2021, 37(5): 394-402.
|
| [19] |
Hyogo H, Roy S, Cohen DE. Restoration of gallstone susceptibility by leptin in C57BL/6J ob/ob mice [J]. J Lipid Res, 2003, 44(6): 1232-1240.
|
| [20] |
Tran KQ, Graewin SJ, Swartz-Basile DA, et al. Leptin-resistant obese mice have paradoxically low biliary cholesterol saturation [J]. Surgery, 2003, 134(2): 372-377.
|
| [21] |
Yu DD, Andrali SS, Li H, et al. Novel FXR (farnesoid X receptor) modulators: Potential therapies for cholesterol gallstone disease [J]. Bioorg Med Chem, 2016, 24(18): 3986-3993.
|
| [22] |
Hu H, Shao W, Liu Q, et al. Gut microbiota promotes cholesterol gallstone formation by modulating bile acid composition and biliary cholesterol secretion [J]. Nat Commun, 2022, 13(1): 252.
|
| [23] |
Dittrick GW, Thompson JS, Campos D, et al. Gallbladder pathology in morbid obesity [J]. Obes Surg, 2005, 15(2): 238-242.
|
| [24] |
Kim MS, Song M, Kim S, et al. Causal effect of adiposity on the risk of 19 gastrointestinal diseases: a Mendelian randomization study [J]. Obesity (Silver Spring), 2023, 31(5): 1436-1444.
|
| [25] |
Yokoe M, Hata J, Takada T, et al. Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholecystitis (with videos) [J]. J Hepatobiliary Pancreat Sci, 2018, 25(1): 41-54.
|
| [26] |
Augustin T, Moslim MA, Brethauer S, et al. Obesity and its implications for morbidity and mortality after cholecystectomy: A matched NSQIP analysis [J]. Am J Surg, 2017, 213(3): 539-543.
|
| [27] |
Al-Azzawi HH, Nakeeb A, Saxena R, et al. Cholecystosteatosis: an explanation for increased cholecystectomy rates [J]. J Gastrointest Surg, 2007, 11(7): 835-42; discussion 842-843.
|
| [28] |
Goldblatt MI, Swartz-Basile DA, Svatek CL, et al. Decreased gallbladder response in leptin-deficient obese mice [J]. J Gastrointest Surg, 2002, 6(3): 438-442; discussion 443-444.
|
| [29] |
Patel SB. Ezetimibe: a novel cholesterol-lowering agent that highlights novel physiologic pathways [J]. Curr Cardiol Rep, 2004, 6(6): 439-442.
|
| [30] |
Mathur A, Al-Azzawi HH, Lu D, et al. Steatocholecystitis: the influence of obesity and dietary carbohydrates [J]. J Surg Res, 2008, 147(2): 290-297.
|
| [31] |
Tsai CJ. Steatocholecystitis and fatty gallbladder disease [J]. Dig Dis Sci, 2009, 54(9): 1857-1863.
|
| [32] |
Hu J, Tang J, Zhang X, et al. Landscape in the gallbladder mycobiome and bacteriome of patients undergoing cholelithiasis with chronic cholecystitis [J]. Front Microbiol, 2023, 14: 1131694.
|
| [33] |
Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies [J]. Lancet, 2008, 371(9612): 569-578.
|
| [34] |
Larsson SC, Wolk A. Obesity and the risk of gallbladder cancer: a meta-analysis. [J]. British Journal of Cancer, 2007, 96(9): 1457-1461.
|
| [35] |
Zatonski WA, Lowenfels AB, Boyle P, et al. Epidemiologic aspects of gallbladder cancer: a case-control study of the SEARCH Program of the International Agency for Research on Cancer [J]. J Natl Cancer Inst, 1997, 89(15): 1132-1138.
|
| [36] |
Ryu S, Chang Y, Yun KE, et al. Gallstones and the Risk of Gallbladder Cancer Mortality: A Cohort Study [J]. Am J Gastroenterol, 2016, 111(10): 1476-1487.
|
| [37] |
Park J, Morley TS, Kim M, et al. Obesity and cancer--mechanisms underlying tumour progression and recurrence [J]. Nat Rev Endocrinol, 2014, 10(8): 455-465.
|
| [38] |
Kitasato A, Tajima Y, Kuroki T, et al. Inflammatory cytokines promote inducible nitric oxide synthase-mediated DNA damage in hamster gallbladder epithelial cells [J]. World J Gastroenterol, 2007, 13(47): 6379-6384.
|
| [39] |
Werner H, Bruchim I. The insulin-like growth factor-I receptor as an oncogene [J]. Arch Physiol Biochem, 2009, 115(2): 58-71.
|
| [40] |
Wang F, Wang B, Qiao L. Association between obesity and gallbladder cancer [J]. Front Biosci (Landmark Ed), 2012, 17(7): 2550-2558.
|
| [41] |
Sharma A, Sharma KL, Gupta A, et al. Gallbladder cancer epidemiology, pathogenesis and molecular genetics: Recent update [J]. World J Gastroenterol, 2017, 23(22): 3978-3998.
|
| [42] |
Stender S, Nordestgaard BG, Tybjaerg-Hansen A. Elevated body mass index as a causal risk factor for symptomatic gallstone disease: a Mendelian randomization study [J]. Hepatology, 2013, 58(6): 2133-2141.
|
| [43] |
Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial [J]. JAMA, 2024, 331(1): 38-48.
|
| [44] |
Mathus-Vliegen EM, Van Ierland-Van Leeuwen ML, Terpstra A. Lipase inhibition by orlistat: effects on gall-bladder kinetics and cholecystokinin release in obesity [J]. Aliment Pharmacol Ther, 2004, 19(5): 601-611.
|
| [45] |
Jonas E, Marsk R, Rasmussen F, et al. Incidence of postoperative gallstone disease after antiobesity surgery: population-based study from Sweden [J]. Surg Obes Relat Dis, 2010, 6(1): 54-58.
|
| [46] |
Alsallamin I, Chakhachiro D, Bawwab A, et al. Prevalence of Symptomatic Gallbladder Disease After Bariatric Surgery: A Literature Review [J]. Cureus, 2023, 15(4): e37777.
|
| [47] |
Moon RC, Teixeira AF, DuCoin C, et al. Comparison of cholecystectomy cases after Roux-en-Y gastric bypass, sleeve gastrectomy, and gastric banding [J]. Surg Obes Relat Dis, 2014, 10(1): 64-68.
|
| [48] |
Erlinger S. Gallstones in obesity and weight loss [J]. Eur J Gastroenterol Hepatol, 2000, 12(12): 1347-1352.
|
| [49] |
Veyrie N, Servajean S, Berger N, et al. Gallbladder complications after bariatric surgery[J]. Gastroenterol Clin Biol, 2007, 31(4): 378-384.
|
| [50] |
Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus [J]. Ann Surg, 2003, 238(4): 467-484; discussion 84-85.
|
| [51] |
Al-Jiffry BO, Shaffer EA, Saccone GT, et al. Changes in gallbladder motility and gallstone formation following laparoscopic gastric banding for morbid obestity [J]. Can J Gastroenterol, 2003, 17(3): 169-174.
|
| [52] |
Jansen PL, van Werven J, Aarts E, et al. Alterations of hormonally active fibroblast growth factors after Roux-en-Y gastric bypass surgery [J]. Dig Dis, 2011, 29(1): 48-51.
|
| [53] |
Tiong L, Oh J. Safety and efficacy of a laparoscopic cholecystectomy in the morbid and super obese patients [J]. HPB (Oxford), 2015, 17(7): 600-604.
|
| [54] |
Wong A, Naidu S, Lancashire RP, et al. The impact of obesity on outcomes in patients undergoing emergency cholecystectomy for acute cholecystitis [J]. ANZ J Surg, 2022, 92(5): 1091-1096.
|
| [55] |
Paajanen H, Käkelä P, Suuronen S, et al. Impact of obesity and associated diseases on outcome after laparoscopic cholecystectomy [J]. Surg Laparosc Endosc Percutan Tech, 2012, 22(6): 509-513.
|
| [56] |
Johansson K, Sundström J, Marcus C, et al. Risk of symptomatic gallstones and cholecystectomy after a very-low-calorie diet or low-calorie diet in a commercial weight loss program: 1-year matched cohort study [J]. Int J Obes (Lond), 2014, 38(2): 279-284.
|
| [57] |
Sulaberidze G, Okujava M, Liluashvili K, et al. Dietary fiber's benefit for gallstone disease prevention during rapid weight loss in obese patients [J]. Georgian Med News, 2014(231): 95-99.
|
| [58] |
Stinton LM, Shaffer EA. Epidemiology of gallbladder disease: cholelithiasis and cancer [J]. Gut Liver, 2012, 6(2): 172-187.
|
| [59] |
Banim PJ, Luben RN, Wareham NJ, et al. Physical activity reduces the risk of symptomatic gallstones: a prospective cohort study [J]. Eur J Gastroenterol Hepatol, 2010, 22(8): 983-988.
|
| [60] |
Lander EM, Wertheim BC, Koch SM, et al. Vegetable protein intake is associated with lower gallbladder disease risk: Findings from the Women's Health Initiative prospective cohort [J]. Prev Med, 2016, 88: 20-26.
|
| [61] |
Uy MC, Talingdan-Te MC, Espinosa WZ, et al. Ursodeoxycholic acid in the prevention of gallstone formation after bariatric surgery: a meta-analysis [J]. Obes Surg, 2008, 18(12): 1532-1538.
|
| [62] |
Stokes CS, Gluud LL, Casper M, et al. Ursodeoxycholic acid and diets higher in fat prevent gallbladder stones during weight loss: a meta-analysis of randomized controlled trials [J]. Clin Gastroenterol Hepatol, 2014, 12(7): 1090-1100 e2; quiz e61.
|
| [63] |
Méndez-Sánchez N, González V, Aguayo P, et al. Fish oil (n-3) polyunsaturated fatty acids beneficially affect biliary cholesterol nucleation time in obese women losing weight [J]. J Nutr, 2001, 131(9): 2300-2303.
|